SpyGlass Pharma, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
SpyGlass reported Q2 2026 cash/equivalents/short-term investments of $234.2M (90.6% of total assets), expected to fund operations through 2028. BIM-IOL System Phase 3 enrollment remains on track for completion in 2027; BIM-DRS first-in-human trial expected H2 2026. Net loss was $19.9M ($0.59/share) in Q2 2026 vs. $8.7M ($3.81/share) in Q2 2025; R&D expenses rose to $10.9M from $7.3M YoY; G&A nearly quintupled to $11.0M from $2.0M. Company appointed Mike Pinder as VP Marketing in June 2026 and obtained dedicated CPT reimbursement code (+1090T) in May 2026.
Why this rating
On-track clinical milestones and CPT code approval are positive operationally, but company remains pre-commercialization with growing burn rate ($37.4M YTD 2026 vs. $16.7M YTD 2025, +123%). Strong cash position ($234M ≈ 90% of assets) provides runway, but near-doubling of losses and elevated operating expenses relative to company scale warrant caution. Routine quarterly progress update.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.